Is not known is the leading cause of cancer deaths among men and women in the United States, with 160,000 deaths estimated in 2007. About 80 to 85 percent of these patients will be diagnosed with non-small cell lung cancer, diagnosed with mainly with locally advanced or metastatic disease.. The results of this study are for presentation at an upcoming submit medical conference.Merck KGaA, Darmstadt, Germany, ImClone ‘s ERBITUX partner outside of North America.About Lungthe American Cancer Society estimates that in the U.S.

Erbitux for the treatment of EGFR-expressing, metastatic colorectal cancer in combination with irinotecan in patients who are refractory to irinotecan-based chemotherapy and as a single agent in patients who are intolerant to irinotecan-based therapy. The effectiveness of Erbitux for the treatment of EGFR-expressing mCRC cancer is based on objective response rates. Currently no data are available that demonstrate an improvement in disease-related symptoms or increased survival with Erbitux for the treatment of EGFR-expressing mCRC.Prevalent diseases: %age of subjects with a personal or family history of the arthritis high blood pressure , diabetic .